SCHEMBL4980334

SCHEMBL4980334

COc1cc2nncc(-n3ncc4ccc(N5CCOCC5)cc43)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.49
MAP4K1 Q92918 3/20 0.45
LRRK2 Q5S007 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
APP P05067 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
PIK3CA P42336 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
THRB P10828 2/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4795126 0.92 PDE10A (0.45) PDE10AMAP4K1LRRK2SMN1; SMN2ALDH1A1
SCHEMBL5652893 0.92 PDE10A (0.49) PDE10AMAP4K1LRRK2SMN1; SMN2APP
SCHEMBL4984909 0.81 PDE10A (0.50) PDE10AMAP4K1SMN1; SMN2APPBCHE
SCHEMBL4794636 0.80 PDE10A (0.49) PDE10ASMN1; SMN2APPBCHEACHE
SCHEMBL5247526 0.79 PDE10A (0.61) PDE10ASMN1; SMN2APPBCHEACHE
SCHEMBL4977732 0.79 IRAK4 (0.42) PDE10ACYP3A4CYP2C19
SCHEMBL5653371 0.78 PDE10A (0.47) PDE10AALDH1A1KDM4ECYP3A4MAPT
SCHEMBL5651040 0.74 FLT1 (0.41) PDE10A
SCHEMBL4778892 0.72 PDE10A (0.67) PDE10A
SCHEMBL5652542 0.72 PDGFRB (0.47) PDE10ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991540-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 EP disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
WO-2007098214-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors PDE7A, PDE10A, PDE7B PDE10A 2/4885MAP4K1 2163/4885LRRK2 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.